Methods: KEYNOTE-158 is a phase 2 basket study investigating the antitumor activity of pembro across several cancer types. Key eligibility criteria for the cervical cancer cohort included histologically or cytologically confirmed disease, progression on or intolerance to ≥1 line of standard therapy, ...
[18]Chung H C,Ros W, Delord J P, et al. Efficacyand safety of pembrolizumab in previouslytreated advanced cervical cancer:results from the phase II KEYNOTE-158study[J]. Journal of Clinical Oncology,2019, 37(17): 1470-1478.
1、从KEYNOTE系列研究看K药发展之路Pembrolizumab(帕博利珠单抗),商品名为Keytruda(可瑞达),俗称K药,截止目前美国食品药品监督管理局(FDA)已批准其用于包括黑色素瘤、非小细胞肺癌、尿路上皮癌等在内的17个癌种/不限癌种的治疗,不限癌种即不按照肿瘤组织来源,而依照生物标志物进行区分的抗肿瘤疗法,是首个真正意义...
[16]Chung H C, Ros W, Delord J P, et al. Efficacyand safety of pembrolizumab in previously treated advanced cervical cancer:results from the phase II KEYNOTE-158 study[J]. Journal of Clinical Oncology,2019, 37(17): 1470-1478. [17]Tabernero J, V...
2. Chung HC, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019 Jun 10;37(17):1470-1478. 3. Colombo N, Dubo...
1. Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab plus chemoradiotherapy high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Presented at: 2024 ESMO Congress; September 12-17, 2024; Bar...
2. Chung HC, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019 Jun 10;37(17):1470-1478. 3. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or met...
Bradley J. Monk, MD, FACS, FACOG, discusses the enrollment criteria and dosing for the phase 3 KEYNOTE-A18 study of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Bradley J. Monk, MD, FACS, FACOG, discusses the phase 3 KEYNOTE-A18 study of pembrolizumab with chemoradiotherapy for the treatment of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer. Bradley J. Monk, MD, FACS, FACOG, a professor in the Divis...
In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8% of 98 patients with previously treated recurrent or metastatic cervical cancer. Serious adverse reactions occurred in 39% of patients receiving KEYTRUDA; the most frequent included anemia (7%), fistula, hemorrhage, and infectio...